Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2022 June;70(3) > Minerva Cardiology and Angiology 2022 June;70(3):385-92

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  DIABETES AND HEART FAILURE 

Minerva Cardiology and Angiology 2022 June;70(3):385-92

DOI: 10.23736/S2724-5683.21.05794-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Reverse remodeling in diabetic cardiomyopathy: the role of extracellular matrix

Ibrahim AYKAC, Bruno K. PODESSER, Attila KISS

Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Vienna, Austria



Diabetic patients are prone to suffer from cardiovascular disease, specifically from ischemic heart disease and diabetic cardiomyopathy, which have a huge impact on morbidity and mortality worldwide. Cardiac fibrosis due to alteration of the extracellular matrix (ECM) remodeling is often observed in diabetes and myocardial fibrosis is an important part of cardiac remodeling that leads to heart failure and death. At single-cell level, the ECM govern, metabolism, motility, orientation, and proliferation. However, in pathological condition such as diabetes, changes in ECM lead to fibrosis and subsequently cardiac stiffness and cardiomyocytes dysfunction. Antidiabetic drugs, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors have antifibrotic effects and may promote ECM reverse remodeling. In this review, the mechanisms, and the role of ECM remodeling and reverse remodeling as a potential therapeutic target for diabetic cardiomyopathy are discussed.


KEY WORDS: Diabetes mellitus; Extracellular matrix; Fibrosis

top of page